# Mira Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2026

- Company: [Mira Pharmaceuticals, Inc.](/companies/mira.md) (CIK 1904286)
- Form: 10-Q
- Filed: 2026-05-14
- Accepted by EDGAR: May 14, 2026, 19:03 ET
- Period: 2026-03-31
- Accession: 0001493152-26-023005
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226023005/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1904286/000149315226023005/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2026-01-01 to 2026-03-31 | $524.8k | us-gaap:ResearchAndDevelopmentExpense |
| Net income | 3 months, 2026-01-01 to 2026-03-31 | −$1.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-01-01 to 2026-03-31 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-01-01 to 2026-03-31 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months, 2026-01-01 to 2026-03-31 | −$1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2026-03-31 | $4.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Cash and equivalents | at 2026-03-29 | $80.8k | us-gaap:Cash |
| Current assets | at 2026-03-31 | $9.4m | us-gaap:AssetsCurrent |
| Total assets | at 2026-03-31 | $9.5m | us-gaap:Assets |
| Current liabilities | at 2026-03-31 | $114.8k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2026-03-31 | $114.8k | us-gaap:Liabilities |
| Shareholders' equity | at 2026-03-31 | $9.3m | us-gaap:StockholdersEquity |

## Market risk

As filed, 196 characters.

The Company is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and therefore is not required to provide the information under this item per Item 305(e) of Regulation S-K.

## Controls and procedures

As filed, 2,750 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report, our management, with the participation of our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer) (the “Certifying Officers”), conducted evaluations of our disclosure controls and procedures. As defined under Sections 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the term “disclosure controls and procedures” means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including the Certifying Officers, to allow timely decisions regarding required disclosures.

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

Based on this evaluation, the Certifying Officers have concluded that our disclosure controls and procedures were effective as of March 31, 2026.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act, during our first quarter of 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 420 characters.

For a discussion of risk factors, please read *Item 1A, “Risk Factors”* in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Such risk factors continue to be relevant to an understanding of our business, financial condition and operating results. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes from the risk factors reported in our 2025 Annual Report.

Filed May 14, 2026.
Source: SEC EDGAR, the filing index for accession 0001493152-26-023005. Last ingested by Listed: Oct 24, 2026, 15:16 ET. No prices; not investment advice.